Company registration number 11097153 (England and Wales)
SAGE UROLOGY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
PAGES FOR FILING WITH REGISTRAR
Sobell Rhodes LLP
The Kinetic Centre
Theobald Street
Elstree
Borehamwood
Hertfordshire
WD6 4PJ
SAGE UROLOGY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
SAGE UROLOGY LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
26,995
29,163
Investments
4
658,151
468,649
685,146
497,812
Current assets
Debtors
5
93,544
58,985
Cash at bank and in hand
162,555
232,683
256,099
291,668
Creditors: amounts falling due within one year
6
(259,361)
(140,881)
Net current (liabilities)/assets
(3,262)
150,787
Total assets less current liabilities
681,884
648,599
Provisions for liabilities
(6,749)
(7,291)
Net assets
675,135
641,308
Capital and reserves
Called up share capital
7
100
100
Profit and loss reserves
675,035
641,208
Total equity
675,135
641,308

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

SAGE UROLOGY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
Mr M Laniado
Director
Company registration number 11097153 (England and Wales)
SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Sage Urology Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/o Sobell Rhodes LLP, Kinetic Business Centre, Theobald Street, Elstree, Hertfordshire, United Kingdom, WD6 4PJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
5
5
SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
64,996
Additions
5,640
At 31 December 2024
70,636
Depreciation and impairment
At 1 January 2024
35,833
Depreciation charged in the year
7,808
At 31 December 2024
43,641
Carrying amount
At 31 December 2024
26,995
At 31 December 2023
29,163
4
Fixed asset investments
2024
2023
£
£
Other investments other than loans
658,151
468,649
Movements in fixed asset investments
Investments
£
Cost or valuation
At 1 January 2024
468,649
Additions
140,000
Valuation changes
49,502
At 31 December 2024
658,151
Carrying amount
At 31 December 2024
658,151
At 31 December 2023
468,649

The historic cost of fixed asset investments at the year end was £60 0,000 (202 3: £46 0,000)

SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
60,713
27,273
Other debtors
2,755
10,739
Prepayments and accrued income
30,076
20,973
93,544
58,985
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
26,022
3,775
Corporation tax
203,833
116,960
Other creditors
13,630
10,875
Accruals and deferred income
15,876
9,271
259,361
140,881
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary share of £1 each
40
40
40
40
B Ordinary share of £1 each
40
40
40
40
C Ordinary share of £1 each
10
10
10
10
D Ordinary share of £1 each
10
10
10
10
100
100
100
100
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
26,056
18,456
SAGE UROLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
9
Related party transactions

During the year dividends totalling £29 8,500 (202 3: £290,000) were paid to the directors and their children in accordance with their shareholdings in the company.

Included within other debtors at the year end is an amount of £13,098 due to the directors (2023: £10,739 due from the directors).No interest is charged on the loan, and it is repayable on demand.

2024-12-31 2024-01-01 false false false 23 December 2025 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr M Laniado Mrs C Laniado 11097153 2024-01-01 2024-12-31 11097153 2024-12-31 11097153 2023-12-31 11097153 core:OtherPropertyPlantEquipment 2024-12-31 11097153 core:OtherPropertyPlantEquipment 2023-12-31 11097153 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 11097153 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 11097153 core:CurrentFinancialInstruments 2024-12-31 11097153 core:CurrentFinancialInstruments 2023-12-31 11097153 core:ShareCapital 2024-12-31 11097153 core:ShareCapital 2023-12-31 11097153 core:RetainedEarningsAccumulatedLosses 2024-12-31 11097153 core:RetainedEarningsAccumulatedLosses 2023-12-31 11097153 core:ShareCapitalOrdinaryShareClass1 2024-12-31 11097153 core:ShareCapitalOrdinaryShareClass1 2023-12-31 11097153 core:ShareCapitalOrdinaryShareClass2 2024-12-31 11097153 core:ShareCapitalOrdinaryShareClass2 2023-12-31 11097153 core:ShareCapitalOrdinaryShareClass3 2024-12-31 11097153 core:ShareCapitalOrdinaryShareClass3 2023-12-31 11097153 core:ShareCapitalOrdinaryShareClass4 2024-12-31 11097153 core:ShareCapitalOrdinaryShareClass4 2023-12-31 11097153 core:ShareCapitalOrdinaryShares 2024-12-31 11097153 core:ShareCapitalOrdinaryShares 2023-12-31 11097153 bus:Director1 2024-01-01 2024-12-31 11097153 core:ComputerEquipment 2024-01-01 2024-12-31 11097153 2023-01-01 2023-12-31 11097153 core:OtherPropertyPlantEquipment 2023-12-31 11097153 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 11097153 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 11097153 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 11097153 bus:OrdinaryShareClass3 2024-01-01 2024-12-31 11097153 bus:OrdinaryShareClass4 2024-01-01 2024-12-31 11097153 bus:OrdinaryShareClass1 2024-12-31 11097153 bus:OrdinaryShareClass1 2023-12-31 11097153 bus:OrdinaryShareClass2 2024-12-31 11097153 bus:OrdinaryShareClass2 2023-12-31 11097153 bus:OrdinaryShareClass3 2024-12-31 11097153 bus:OrdinaryShareClass3 2023-12-31 11097153 bus:OrdinaryShareClass4 2024-12-31 11097153 bus:OrdinaryShareClass4 2023-12-31 11097153 bus:AllOrdinaryShares 2024-12-31 11097153 bus:AllOrdinaryShares 2023-12-31 11097153 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 11097153 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 11097153 bus:FRS102 2024-01-01 2024-12-31 11097153 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 11097153 bus:Director2 2024-01-01 2024-12-31 11097153 bus:FullAccounts 2024-01-01 2024-12-31 xbrli:pure xbrli:shares iso4217:GBP